Research News

Medscape - Alexandre Malek, MD, assistant professor of medicine at LSUHS, pointed to "a growing number of preclinical studies evaluating the role of vaccines as adjunct to immunotherapy to overcome cancer resistance by converting cold tumors to hot." That research includes a study of a seasonal influenza vaccine and another of adenoviral based-vaccines.

Louisiana Radio Network - After a recent report from the LSUHS Louisiana Addiction Research Center showing Shreveport’s wastewater contained double the amount of methamphetamine than anywhere else in the country, many were shocked. 

National and Local News Report: LSUHS is now enrolling participants in a Phase 3 clinical trial to compare the effectiveness of standard flu vaccine to an investigational mRNA flu vaccine until mid-December. 

LSUHS Louisiana Addiction Research Center hosted a meeting on Wednesday, Nov. 9, to discuss methamphetamine as an emerging drug threat in our region. Local law enforcement and community leaders were invited to have an open conversation and share information on drug problems in the region and determine how to raise awareness.

Dr. Chris Kevil’s laboratory at LSUHS has discovered that a clinically approved cyclodextrin-based drug called Sugammadex can act as a hydrogen sulfide donor that restores vasoactive hydrogen. This innovation has already gone through initial in vivo testing with promising results.

“Medicine in general is considerably complex and neurosurgery is extremely complex, with cavernous malformations among the most difficult to manage,” said Dr. Caleb Stewart, neurosurgeon at LSUHS. LSUHS, LSUS, Ochsner Health, and collaborators in Australia are now leveraging big data science and artificial intelligence (AI) to solve this challenge and improve care for patients.

The LSU Health Shreveport Department of Otolaryngology/Head & Neck Surgery led by Chair Dr. Cherie-Ann Nathan has received notification of manuscript CCR-21-4290R1 being selected for publication in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Medscape - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS talks with Medscape about the importance of virology in addressing concerns over hot topic viruses.

The Louisiana Board of Regents has supported full five-year approval for the Louisiana Addiction Research Center (LARC) and Center for Emerging Viral Threats (CEVT), with the CEVT continuing to be a designated Center of Research Excellence. The Board of Regents approval follows unanimous approval of both centers by the LSU Board of Supervisors earlier this year. Both centers were previously granted provisional approval and applied for full center approval earlier this year.

The Center of Excellence for Emerging Viral Threats’ (CEVT) Viral Genomics and Surveillance Lab has surpassed uploading its’ 15,000^th sequence to GISAID (Global Initiative on Sharing Influenza Data). The LSU Health Shreveport CEVT team has worked tirelessly since early in the COVID-19 pandemic to sequence and track variants of SAR-CoV-2, the virus that causes the COVID-19 disease.

A massive new study spotlights the toll methamphetamine use may take on heart health, suggesting men, people with kidney disease and those with high blood pressure are especially at risk. While researchers don't fully understand how meth use increases the risk for heart problems, they do know it creates a lot of stress on the body, shared Dr. Chris Kevil, LSUHS Vice Chancellor for Research.

The Scientist - A new tool called PRISM draws on virus-host interactions and a DNA repair pathway to help researchers visualize how cellular stress may contribute to neurodegenerative disease.

The Center for Brain Health at LSUHS has received a $100,000 gift to create the Noel Foundation, Inc. Endowed Professorship Honoring Dr. Robert C. Leitz, III in Parkinson’s Disease Research. It will expand the study of age-related neurodegenerative diseases and fund neurological training equipment for students studying at LSUHS. 

LAS VEGAS, June 7, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that a patent was issued that covers a method of improving nerve function using JAN101.

This prestigious award, sponsored by the American Heart Association’s Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB Council), recognizes investigators in the formative years of their faculty careers who have the potential to become future leaders in cardiovascular research.